This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
DGX delivers solid top-line growth in the first quarter of 2025.
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 2.79% and 1.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings
by Zacks Equity Research
DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.
DGX Stock Gains Following the Launch of New AD-Detect Blood Test
by Zacks Equity Research
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.
Is Quest Diagnostics Stock Worth Holding Onto Right Now?
by Zacks Equity Research
Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.
DGX Stock Set to Benefit From New Google Cloud Partnership
by Zacks Equity Research
Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI.
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
by Urmimala Biswas
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
Aveanna (AVAH) Surges 6.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Aveanna (AVAH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge?
by Zacks Equity Research
DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
by Zacks Equity Research
DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy.
Take the Zacks Approach to Beat the Markets: Nomura, Wells Fargo, Primo Brands in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise
by Zacks Equity Research
Insulet's fourth-quarter results benefit from the continued high demand for Omnipod 5.
ICLR Q4 Earnings and Revenues Beat, Stock Rises at After-Market
by Zacks Equity Research
ICON's fourth-quarter 2024 earnings and revenues beat estimates as it manages to navigate a challenging transition period.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
by Zacks Equity Research
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Should You Hold IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
by Zacks Equity Research
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
by Zacks Equity Research
Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.
DVA Q4 Estimates Unchanged Before Earnings: How to Play the Stock?
by Zacks Equity Research
Continued strength in RPT is likely to have boosted DaVita's top line in the fourth quarter despite supply challenges weighing on its performance.
EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash
by Zacks Equity Research
Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in the fourth quarter of 2024.
Should You Add Penumbra Stock to Your Portfolio Right Now?
by Zacks Equity Research
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.